Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)

Chest

Volumn 132, Issue 3 SUPPL., 2007, Pages 314S-323S

  Samson, David J ^a   Seidenfeld, Jerome ^a   Simon, George R ^b   Turrisi III, Andrew T ^c   Bonnell, Claudia ^a   Ziegler, Kathleen M ^a   Aronson, Naomi ^d  

^a Blue Cross and Blue Shield Association   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d NONE

Author keywords

Carboplatin; Chemotherapy; Cisplatin; Etoposide; Irinotecan; Meta analysis; Paclitaxel; Prophylactic cranial irradiation; Radiation therapy; Small cell lung cancer; Systematic review

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; LOMUSTINE; METHOTREXATE; PLATINUM DERIVATIVE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; COMBINATION CHEMOTHERAPY; ESOPHAGITIS; HUMAN; LUNG SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SKULL IRRADIATION; SYSTEMATIC REVIEW; BRAIN TUMOR; EVIDENCE BASED MEDICINE; LUNG TUMOR; METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SMALL CELL CARCINOMA; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, SMALL CELL; CRANIAL IRRADIATION; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS;

EID: 34848911031     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1384     Document Type: Article

References (87)

1. American Cancer Society. Cancer facts and figures 2005. Atlanta, GA: American Cancer Society, 2005. Available at: http://www.cancer.org/downloads/ STT/CAFF2005f4PWSecured.pdf. Accessed June 15, 2005
2. Murren JR, Turrisi AT, Pass HI. Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 7th ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2005; 810-843
3. Simon GR, Wagner H, for the American College of Chest Physicians. Small cell lung cancer. Chest 2003; 123(suppl): 259S-271S
4. National Cancer Institute, National Institutes of Health. Physicians data query (PDQ): small cell lung cancer treatment (health professional version); last modified May 17, 2005. Available at: http://cancernet.nci.nih.gov/ cancertopics/pdq/treatment/small-cell-lung/healthprofessional. Accessed June 15, 2005
5. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev 2004; 30:521-543
6. Ettinger DS. Overview and state of the art in the management of lung cancer. Oncology (Huntingt) 2004; 18(suppl 4):3-9
7. Stupp R, Monnerat C, Turrisi AT III, et al. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004; 45:105-117
8. National Comprehensive Cancer Network. National Comprehensive Cancer Network practice guidelines in oncology v. 1.2007: small cell lung cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf. Accessed January 9, 2007
9. Osterlind K. Chemotherapy in small cell lung cancer. Eur Respir J 2001; 18:1026-1043
10. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890-895
11. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618-1624
12. Turrisi AT III. Platinum combined with radiation therapy in small cell lung cancer: focusing like a laser beam on crucial issues. Semin Oncol 1994; 21(suppl):36-42
13. Cancer Care Ontario. The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small cell lung cancer: update; January 2003. Available at: //www.cancercare.on.ca/pdf/full7_13_3.pdf. Accessed December 20, 2005
14. Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist, 2004; 9:665-672
15. Pijls-Johannesma MCG, De Ruysscher D, Lambin P, et al. Early vs late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev (database online). Issue 4, 2004
16. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22:4837-4845
17. Livingston RB, Mira JG, Chen TT, et al. Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1984; 2:585-590
18. Livingston RB, Schulman S, Mira JG, et al. Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: a Southwest Oncology Group Study. Cancer Treat Rep 1986; 70:1395-1401
19. Carney DN. Prophylactic cranial irradiation and small-cell lung cancer. N Engl J Med 1999; 341:524-526
20. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20(suppl):21-35
21. Whiting P, Rutjes AWS, Dinnes J, et al. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004; 8:1-248
22. Seidenfeld J, Samson DJ, Bonnell CJ, et al. Management of small cell lung cancer: evidence report/technology assessment No. 143; prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-Based Practice Center under contract 290-02-0026. Rockville, MD: Agency for Healthcare Research and Quality, 2006; AHRQ publication 06-E016
23. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent vs sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20:3054-3060
24. Park SK, Kim GH, Jeong SS, et al. The effects according to the timing of thoracic radiotherapy in limited stage small cell lung cancer. Tuberc Respir Dis 1996; 43:903-915
25. Sun Y, Zhang XR, Yin WB, et al. Prospective multimodality treatment of SCLC: experience during the past 18 years. Gan To Kagaku Ryoho 1995; 22(suppl):222-225
26. Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating vs sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol 1997; 15:2840-2849
27. Lebeau B, Chastang C, Brechot JM, et al. A randomized trial of delayed thoracic radiotherapy in complete responder patients with small-cell lung cancer: petites Cellules Group. Chest 1993; 104:726-733
28. Blackstock AW, Bogart JA, Matthews C, et al. Split-course vs continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial. Clin Lung Cancer 2005; 6:287-292
29. Work E, Nielsen OS, Bentzen SM, et al. Randomized study of initial vs late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer: Aarhus Lung Cancer Group. J Clin Oncol 1997; 15:3030-3037
30. Work E, Bentzen SM, Nielsen OS, et al. Prophylactic cranial irradiation in limited stage small cell lung cancer: survival benefit in patients with favourable characteristics. Eur J Cancer 1996; 32A:772-778
31. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11:336-344
32. Coy P, Hodson DI, Murray N, et al. Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1994; 28:355-362
33. Feld R, Payne D, Hodson I, et al. Complications of treatment of small cell carcinoma of the lung: experience from a recent Canadian trial. Antibiot Chemother 1988; 41:204-209
34. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912-918
35. Ahles TA, Silberfarb PM, Rundle AC, et al. Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B. Psychother Psychosom 1994; 62:193-199
36. Perry MC, Herndon JE III, Eaton WL, et al. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998; 16:2466-2467
37. Jeremic B, Shibamoto Y, Acimovic L, et al. Initial vs delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15:893-900
38. Qiao TK, Zhou DA, Xin L, et al. Concurrent radiotherapy combined with carboplatin and etoposide in limited stage small cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 2004; 27:237-239
39. Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early vs late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2001; 12:1231-1238
40. James LE, Spiro S, O'Donnell KM, et al. A randomised study of timing of thoracic irradiation in small cell lung cancer (SCLC): study 8. Lung Cancer 2003; 41(Suppl 2):S23
41. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-271
42. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000; 89:1953-1960
43. Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59:943-951
44. Sloan JA, Bonner JA, Hillman SL, et al. A quality-adjusted reanalysis of a phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52:371-381
45. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation vs once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999; 17:2681-2691
46. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999; 17:2092-2099
47. Nou E, Brodin O, Bergh J. A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens. Cancer 1988; 62:1079-1090
48. Lebeau B, Chastang C, Brechot JM, et al. A randomized trial of delayed thoracic radiotherapy in complete responder patients with small-cell lung cancer: petites Cellules Group. Chest 1993; 104:726-733
49. Rosenthal MA, Tattersall MHN, Fox RM, et al. Adjuvant thoracic radiotherapy in small cell lung cancer: ten-year follow-up of a randomized study. Lung Cancer 1991; 7:235-241
50. Brincker H, Hindberg J, Hansen PV. Cyclic alternating polychemotherapy with or without upper and lower half-body irradiation in small cell anaplastic lung cancer: a randomized study. Eur J Cancer Clin Oncol 1987; 23:205-211
51. Prophylactic Cranial Irradiation Overview Collaborative Group. Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission. Cochrane Database Syst Rev 2000; 4:CD002805
52. Cao K, Huang H, Tu M. Clinical study of prophylactic cranial irradiation for small-cell lung cancer. Zhonghua Zhong Liu Za Zhi 2000; 22:336-338
53. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; 22:3248-3254
54. Brink I, Schumacher T, Mix M, et al. Impact of (18F)FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31:1614-1620
55. Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003; 44:1911-1917
56. Shen YY, Shiau YC, Wang JJ, et al. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 2002; 22:1257-1264
57. Blum R, MacManus MP, Rischin D, et al. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 2004; 27:164-171
58. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28:483-488
59. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994; 106(6 suppl):320S-323S.
60. Liao M, Zhao J, Zhou Y. Multimodality therapy of late stage lung cancer. Zhonghua Zhong Liu Za Zhi 1995; 17:384-386
61. Badzio A, Kurowski K, Karnicka-Mlodkowska H, et al. A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 2004; 26:183-188
62. Badzio A, Jassem J, Kurowski K, et al. The impact of primary pulmonary resection on local control and survival in limited disease (LD) small cell lung cancer (SCLC) patients (pts): a retrospective comparative study. Lung Cancer 2005; 49(suppl 2):S316
63. Shepherd FA, Ginsberg RJ, Patterson GA, et al. A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. a University of Toronto Lung Oncology Group study. J Thorac Cardiovasc Surg 1989; 97:177-186
64. Namikawa S, Den T, Kimura M, et al. The role of surgical resection and the effects of neo-adjuvant therapy in the management of small cell lung cancer. Surg Today 1994; 24:342-346
65. Hara N, Ichinose Y, Kuda T, et al. Long-term survivors in resected and nonresected small cell lung cancer. Oncology 1991; 48:441-447
66. Hara N, Ohta M, Ichinose Y, et al. Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol 1991; 47:53-61
67. Friess GG, McCracken JD, Troxell ML, et al. Effect of initial resection of small-cell carcinoma of the lung: a review of Southwest Oncology Group Study 7628. J Clin Oncol 1985; 3:964-968
68. Osterlind K, Hansen M, Hansen HH, et al. Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive patients. Thorax 1985; 40:272-277
69. Rostad H, Naalsund A, Jacobsen R, et al. Small cell lung cancer in Norway: should more patients have been offered surgical therapy? Eur J Cardiothorac Surg 2004; 26:782-786
70. George TK, Fitzgerald D, Brown BS, et al. Long-term survival in limited-stage small cell lung carcinoma: experience in Rochester, New York from 1975 to 1981. Cancer 1986; 58:1193-1198
71. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase ii comparator study of oral vs intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19:1743-1749
72. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan vs cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667
73. Postmus PE, Smit EF, Kirkpatrick A, et al. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993; 29A:204-207
74. Trillet-Lenoir V, Lasset C, Arpin D, et al. Comparison of 2 cisplatin and etoposide dosages in relapsing small cell lung cancer [in French]. Bull Cancer 1992; 79:1173-1181
75. O'Bryan RM, Crowley JJ, Kim PN, et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer: a Southwest Oncology Group Study. Cancer 1990; 65:856-860
76. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989; 59:578-583
77. Sculier JP, Lafitte JJ, Lecomte J, et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol 2002; 13:1454-459
78. O'Brien M, Ciuleanu T, Tsekov H, et al. Survival benefit of oral topotecan plus supportive care vs supportive care alone in relapsed, resistant SCLC. Lung Cancer 2005; 49(Suppl 2):S54
79. Wolff SN, Birch R, Sarma P, et al. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70:583-587
80. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease: the European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090-2096
81. Ando M, Kobayashi K, Yoshimura A, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004; 44:121-127
82. Kosmas C, Tsavaris NB, Malamos NA, et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001; 19:119-126
83. Kakolyris S, Mavroudis D, Tsavaris N, et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 2001; 12:193-197
84. Sonpavde G, Ansari R, Walker P, et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol 2000; 23:68-70
85. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 2007; 132:314-329
86. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Chem 2003; 49:1-6
87. Bossuyt PM, Reitsma JB, Bruns DE et al. The STARD statement for reporting of studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003; 49:7-18